First year real life experience with tenofovir alafenamide fumarate: The pythagorean cohort

Basit Öğe Kaydı
dc.authorid0000-0002-4245-1534en_US
dc.authorid0000-0001-5136-9148en_US
dc.authorid0000-0001-7045-1462en_US
dc.authorid0000-0002-2915-4666en_US
dc.authorid0000-0002-9415-147Xen_US
dc.authorid0000-0003-0994-4465en_US
dc.authorid0000-0002-0760-5681en_US
dc.authorid0000-0003-2419-3436en_US
dc.authorid0000-0001-5876-2241en_US
dc.contributor.authorKaraşahin, Ömer
dc.contributor.authorKalkan, İrem Akdemir
dc.contributor.authorDal, Tuba
dc.contributor.authorToplu, Sibel Altunışık
dc.contributor.authorHarputluoğlu, Murat
dc.contributor.authorMete, Ayşe Özlem
dc.contributor.authorAktar, Fesih
dc.contributor.authorDemir, Yakup
dc.contributor.authorÇelen, Mustafa Kemal
dc.date.accessioned2023-10-31T08:10:39Z
dc.date.available2023-10-31T08:10:39Z
dc.date.issued2023en_US
dc.departmentDicle Üniversitesi, Tıp Fakültesi, Dahili Tıp Bilimleri Bölümü, Çocuk Sağlığı ve Hastalıkları Ana Bilim Dalıen_US
dc.description.abstractBackground and Aim: In chronic hepatitis B infection, antiviral therapy significantly reduces the incidence of complications. This study aimed to present real-life 12-month effectiveness and safety data for TAF. Materials and Methods: This Pythagoras Retrospective Cohort Study included patients from 14 centers in Turkiye. The study presents 12-month results of 480 patients treated with TAF as initial therapy or after switching from another antiviral drug. Results: The study shows treatment of about 78.1% patients with at least one antiviral agent (90.6% tenofovir disoproxil [TDF]). The rate of unde-tectable HBV DNA increased in both treatment-experienced and naive pa-tients. In TDF-experienced patients, the rate of alanine transaminase (ALT) normalization increased slightly (1.6%) within 12 months, but the change was not statistically significant (p=0.766). Younger age, low albumin, and high body mass index and cholesterol were identified as risk factors for abnormal ALT after 12 months, but no linear relationship was detected. In TDF-experienced patients, renal and bone function indicators showed significant improvement three months after the transition to TAF and remained stable for 12 months. Conclusion: Real-life data demonstrated effective virological and biochemical responses with TAF therapy. After switching to TAF treat-ment, gains in kidney and bone functions were achieved in the early period.en_US
dc.identifier.citationKaraşahin, Ö., Kalkan, İ., A., Dal, T., Toplu, S. A., Harputluoğlu, M., Mete, A. Ö. ve diğerleri. (2023). First year real life experience with tenofovir alafenamide fumarate: The pythagorean cohort. Hepatology Forum, 4(2), 61-68.en_US
dc.identifier.doi10.14744/hf.2022.2022.0043
dc.identifier.endpage68en_US
dc.identifier.issn2757-7392
dc.identifier.issue2en_US
dc.identifier.pmid37250926
dc.identifier.scopus2-s2.0-85164340106
dc.identifier.scopusqualityQ3
dc.identifier.startpage61en_US
dc.identifier.trdizinid1178904
dc.identifier.urihttps://hepatologyforum.org/storage/upload/pdfs/1684399387-en.pdf
dc.identifier.urihttps://hdl.handle.net/11468/13003
dc.identifier.volume4en_US
dc.identifier.wosWOS:001000795000004
dc.identifier.wosqualityN/A
dc.indekslendigikaynakWeb of Science
dc.indekslendigikaynakScopus
dc.indekslendigikaynakPubMed
dc.indekslendigikaynakTR-Dizin
dc.institutionauthorAktar, Fesih
dc.institutionauthorDemir, Yakup
dc.institutionauthorÇelen, Mustafa Kemal
dc.language.isoenen_US
dc.publisherKare Publishingen_US
dc.relation.ispartofHepatology Forum
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/openAccessen_US
dc.subjectHepatitis Ben_US
dc.subjectReal lifeen_US
dc.subjectTenofovir alafenamideen_US
dc.titleFirst year real life experience with tenofovir alafenamide fumarate: The pythagorean cohorten_US
dc.titleFirst year real life experience with tenofovir alafenamide fumarate: The pythagorean cohort
dc.typeArticleen_US

Dosyalar

Orijinal paket
Listeleniyor 1 - 1 / 1
Küçük Resim
İsim:
First year real life experience with tenofovir alafenamide.pdf
Boyut:
1.05 MB
Biçim:
Adobe Portable Document Format
Açıklama:
Makale Dosyası
İndir
Lisans paketi
Listeleniyor 1 - 1 / 1
[ X ]
İsim:
license.txt
Boyut:
1.44 KB
Biçim:
Item-specific license agreed upon to submission
Açıklama:
İndir

Koleksiyon

Dahili Tıp Bilimleri Koleksiyonu
PubMed İndeksli Yayın Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu
TR-Dizin İndeksli Yayınlar Koleksiyonu
WoS İndeksli Yayınlar Koleksiyonu